AzTrials
AzTrials

Infertility, MaleMACS-HSNCT03988361

Selection of Non Apoptotic Human Sperm for in Vitro Fertilization by Using Magnetic Activated Cell Sorting (MACS)

An observational study of Infertility, Male, run by Universitair Ziekenhuis Brussel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This clinical study has been organised to help improve the embryo quality in couples having high rate of sperm showing apoptotic signs. For this, the investigators intend to use a procedure (MACS: magnetic-activated cell sorting) that allows the identification and the removal of the apoptotic sperm cells. Read more about this study

Who is it for?
Ages 18 to 43 yearsHealthy volunteers can take part
Conditions the study is for
Infertility, Male
What is being tested?
Magnetic Activated Cell Sorting
How many people
30 participants
Where
No sites listed yet
Study dates
1 Sep 2019to 1 Oct 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 43 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Couples with poor embryo quality in the previous cycle at Centre of reproductive Medicine -Universitair Ziekenhuis Brussel and minimum 30% DNA fragmentation in the previous diagnostic semen analysis.

10.2 Inclusion Criteria

  • Patients with poor embryo quality in the previous cycles:
  • Cycles with no embryo transfer due to insufficient embryo quality
  • "Freeze all" cycles without cryopreservation
  • Cycles with transfer of embryos with fair and/or poor quality
  • Previous diagnostic semen analysis with minimum 30% DNA fragmentation
  • ICSI cycles with fresh ejaculated semen with ≥1 mil spermatozoa after DGC.
  • Minimum 6 mature oocytes after oocyte pick up.

10.3 Exclusion Criteria

  • Cycles with frozen semen sample
  • Cycles with testicular sample
  • In vitro fertilization (IVF) cycles
  • Cycles with pre-implantation genetic diagnosis
  • In vitro maturation cycles

Trial locations and contacts

No sites are listed yet.

About this study

Official title: Evaluation of Embryo Quality After Enrichment of Non-apoptotic Spermatozoa Using Magnetic-activated Cell Sorting (MACS): Study on Sibling Oocytes.

This clinical study has been organised to help improve the embryo quality in couples having high rate of sperm showing apoptotic signs. For this, the investigators intend to use a procedure (MACS: magnetic-activated cell sorting) that allows the identification and the removal of the apoptotic sperm cells. This procedure will increase the chance of using non-apoptotic sperm during in vitro fertilization via Intracytoplasmic Sperm Injection (ICSI). By using this procedure the investigators aim to increase the rate of embryos with good quality for these particular couples.

Read the detailed description

Studies of infertile couples have demonstrated that male factor plays a role in infertility. Spermatozoa can present damages at molecular levels that have an effect on fertilization and embryo development. One of these molecular damages is represented by DeoxyriboNucleic Acid (DNA) fragmentation whose negative impact on embryological outcome appears during genome activation after fertilization and is also correlated with increased miscarriage rate.

DNA fragmentation represents one of the late manifestations of apoptosis. Identification of spermatozoa showing DNA fragmentation (apoptotic spermatozoa) requires fixation and staining. Therefore this method cannot be applied in clinical practice to select for non-apoptotic spermatozoa for ICSI. However, this selection is possible by using magnetic-activated cell sorting (MACS). The procedure is based on the identification and depletion of spermatozoa showing the early marker of apoptosis, namely the externalization of phosphatidylserine (PS), by using the ability of Annexin V to recognize this antigen in the plasma membrane of apoptotic sperm cells. After MACS, the fraction that is enriched in non-apoptotic cells (Annexin V-negative cells) can be further used for clinical application.

The MACS system makes use of a separation column placed in a magnetic field, and of Annexin-V reagent labeled with paramagnetic beads.

Initially, the semen sample will be subject to Density Gradient Centrifugation (DGC). The sample obtained will be divided in 2 fractions: one fraction will be subject to magnetic sorting (fraction 1) and the other fraction will represent the control (no sorting; fraction 2).

The cells from fraction 1 will be incubated with Annexin-V and then passed through the separation column located in a magnetic field. The apoptotic cells (Annexin V-positive cells) will be selectively retained in the column. The non-apoptotic cells, not being labeled by Annexin V, will pass through the column and will be collected for further use.

At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from fraction 1 (enriched in non-apoptotic cells) or from fraction 2 (control, conventionally prepared spermatozoa). Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.

The present study aims to determine whether the use of MACS improves the embryo quality/utilization rate in couples with high sperm DNA fragmentation rate. To avoid inter-patient variation, the study is design as a sibling oocyte study. Descriptive statistics will be performed by analysing median, mean, proportions, standard deviation, ranges and 95% confidence intervals as appropriate. Standard parametric and non-parametric tests will be used, as appropriate, to compare primary and secondary outcomes between groups. Sample size calculation: a number of 142 mature oocytes in each arm will be necessary to achieve 80% power of detecting, as significant at the 5% level, an increase in the primary outcome measure from 13% in the control group to 26% in the experimental group.

Being tested
Magnetic Activated Cell Sorting
Medical subject headings
Infertility, Male

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Magnetic Activated Cell SortingDiagnostic test

    At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.

Study groups in NCT03988361
Study groupRoleWhat they receive
Control groupHalf of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
Study groupHalf of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS. The sperm used in this group is considered to be enriched in non apoptotic cells.
Receives: Diagnostic Test: Magnetic Activated Cell Sorting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. utilization rate

    number of transferred and cryopreserved embryos per mature oocytes

    Measured: 2 years

Secondary outcomes (1)
  1. fertilization rate

    number of fertilized oocytes per number of injected oocytes

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2019
  2. Study start1 Sep 2019 (estimated)
  3. Primary completion1 Oct 2021 (estimated)
  4. Study completion1 Oct 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03988361
Sponsor's protocol ID
2018-183
Acronym
MACS-HS
Status last verified
Jun 2019
First submitted
13 Jun 2019
Last updated
21 Jun 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Infertility, Male, run by Universitair Ziekenhuis Brussel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ileana Mateizel, PhD (003224749119, ileana.mateizel@uzbrussel.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

utilization rate (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in